紫杉类与蒽环类药物联合治疗三阴性乳腺癌疗效分析.pdf

《紫杉类与蒽环类药物联合治疗三阴性乳腺癌疗效分析.pdf》由会员上传分享，免费在线阅读，更多相关内容在应用文档-天天文库。

1、中国中西医结合外科杂志2014年6月第2O卷第3期紫杉类与蒽环类药物联合治疗三阴性乳腺癌疗效分析肖宝强，刘晶晶，史振东，张晟摘要目的：比较紫杉类和蒽环类药物联合与单纯蒽环类药物治疗三阴性乳腺癌的疗效。方法：585例三阴性乳腺癌患者中，术后行紫杉联合蒽环类辅助化疗228例，蒽环类辅助化疗357例，分析其复发、转移和生存情况。结果：紫杉联合蒽环类组与蒽环类组患者复发率、转移率与死亡率分别为7．9％与13．2％、21．9％与35．9％、18．0％与28．6％(P<0．05)，与蒽环类方案相比，紫杉联合蒽环类方案延长了临床II、III期、非特殊型浸润性癌、淋巴结阳性患者的总生存

2、期，提高了总生存率。结论：紫杉类与蒽环类药物联合辅助化疗，对于具有晚临床分期、非特殊型浸润性癌及淋巴结阳性特征的三阴性乳腺癌有显著的治疗效果。关键词：紫杉类药；蒽环类药；三阴性乳腺癌；辅助化疗中图分类号：R737．9文献标识码：A文章编号：1007—6948(2014)03—0230—05doi：10．39696．issn．1007-6948．2014．03．002Comparativestudyofthecombinedchemotherapywithtaxanesandantracyclinedrugsfortriple—。nega-tivebreastcancer

3、XIAOBao—qiang，LIUJing-jing，SHIZhen-dong，eta1．DepartmentofBreastCancer,TianjinBreastCancerPrevention,TreatmentandResearchCenter,TianjinMedicalUniversityCancerInstituteandHospital,NationalClinicalResearchCenterofCancer,Tianjin(300060)，ChinaAbstract：ObjectiveToinvestigatetheantitumorefficac

4、yoftaxanesandantracyclinedrugsintriple——nega-tivebreastcancer．MethodsOf585patientswithhistopathologicallyconfirmedresectabletriple—negativebreastcancer，228patientsreceivedadjuvantchemotherapywithtaxanesplusantracycline，andtheother357pa—tientsreceivedantracyclineadjuvantchemotherapy．There

5、currencerate，distantmetastasisrateandmortalityratebetweentwogroupswereanalyzed．Theimpactofthetwochemotherapyregimensonprognosisofpatientsindifferentclinicalstages，pathologictypesandlymphnodestageswasfurtherinvestigated．ResultsTherecur—rencerate，distantmetastasisrateandmortalityratewere7．

6、9％VS13．2％，21．9％VS35．9％and18．0％VS28．6％intaxanesplusantracyclinegroupandsingleantracyclinegroup，respectively．Thedifferenceswerestatisticallysignificant<0．05)．Taxanesplusantracyclineadjuvantchemotherapyimprovedfavorablythepatientsinclini—calstagesIIandIII，orthepatientswithanon-specialinvasi

7、vetypeorlymphaticmetastasis，overallsurvivaltimeandsurvivalrateincomparisonwithsingleantracyclinedrugtreatmentgroup．ConclusionComparedwithanthracyclineregimens．theeffectoftaxanescombinedanthracyclinewasmoreprominentinlaterclinicalstage，non-specialtypeinvasivebreastcarcinom